RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis - RIFUND-MS A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2018
At a glance
- Drugs Dimethyl fumarate (Primary) ; Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms RIFUND-MS
- 01 Sep 2016 Status changed from not yet recruiting to recruiting.
- 18 Apr 2016 Status changed from recruiting to not yet recruiting.
- 13 Apr 2016 New trial record